Европейский союз - мальтийский - EMA (European Medicines Agency)

merck sharp & dohme b.v. - sugammadex - imblokk neuromuskolari - il-prodotti terapewtiċi l-oħra kollha - it-treġġigħ lura ta 'imblokk newromuskolari kkawżat minn rocuronium jew vecuronium. għall-popolazzjoni pedjatrika: sugammadex hu rakkomandat biss għat-treġġigħ lura ta 'rutina ta' imblokk ikkaġunat minn rocuronium indotta mill-imblokk fit-tfal u l-adoloxxenti.

Европейский союз - мальтийский - EMA (European Medicines Agency)

ucb pharma s.a.   - rotigotine - restless legs syndrome; parkinson disease - mediċini kontra l-parkinson - leganto huwa indikat għat-trattament sintomatiku ta 'sindromu idjopatiku moderat għal sever idjopatiku fl-adulti. leganto huwa indikat għat-trattament tas-sinjali u s-sintomi tal-istadju bikri tal-marda idjopatika ta ' parkinson bħala monoterapija (i. mingħajr levodopa) jew flimkien ma 'levodopa, i. matul il-kors tal-marda, permezz ta'l-aħħar stadji meta l-effett ta ' levodopa jonqos ħafna jew isir inkonsistenti u l-varjazzjonijiet tal-effett terapewtiku jseħħu (fl-aħħar tad-doża jew 'on-off' varjazzjonijiet).

Европейский союз - мальтийский - EMA (European Medicines Agency)

mylan ireland limited - sugammadex sodium - imblokk neuromuskolari - il-prodotti terapewtiċi l-oħra kollha - reversal of neuromuscular blockade induced by   rocuronium or vecuronium in adults. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.

Европейский союз - мальтийский - EMA (European Medicines Agency)

fresenius kabi deutschland gmbh - sugammadex sodium - imblokk neuromuskolari - il-prodotti terapewtiċi l-oħra kollha - reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.

Европейский союз - мальтийский - EMA (European Medicines Agency)

piramal critical care b.v. - sugammadex sodium - imblokk neuromuskolari - sugammadex - reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults.

Европейский союз - мальтийский - EMA (European Medicines Agency)

extrovis eu ltd. - sugammadex sodium - imblokk neuromuskolari - il-prodotti terapewtiċi l-oħra kollha - reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.

Европейский союз - мальтийский - EMA (European Medicines Agency)

abbvie deutschland gmbh co. kg - adalimumab - spondylitis, ankylosing; arthritis, juvenile rheumatoid; uveitis; colitis, ulcerative; psoriasis; arthritis, psoriatic; crohn disease; arthritis, rheumatoid - immunosoppressanti - jekk jogħġbok irreferi għad-dokument ta 'informazzjoni dwar il-prodott.

Европейский союз - мальтийский - EMA (European Medicines Agency)

biocryst - peramivir - influwenza, bniedem - antivirali għal użu sistemiku - alpivab huwa indikat għall-kura ta mhux ikkomplikati-influwenza fl-adulti u tfal mill-età ta ' 2 snin.

Европейский союз - мальтийский - EMA (European Medicines Agency)

gilead sciences ireland uc - elvitegravir, kobikistat, emtricitabine, tenofovir alafenamide - infezzjonijiet ta 'hiv - antivirali għal użu sistemiku - genvoya huwa indikat għall-kura ta ' l-adulti u l-adolexxenti (korp età 12-il sena u aktar antiki mal-piż mill-anqas 35 kg) infettati bil-virus ta ' immunodefiċjenza umani 1 (hiv 1) mingħajr ebda mutazzjonijiet magħrufa assoċjati mal-reżistenza għall-klassi ta ' inibitur ta ' integrase, emtricitabine jew tenofovir.

Европейский союз - мальтийский - EMA (European Medicines Agency)

pfizer limited - pneumococcal oligosaccharide serotype 18c, pneumococcal polysaccharide serotype 19f, pneumococcal polysaccharide serotype 23f, pneumococcal polysaccharide serotype 4, pneumococcal polysaccharide serotype 6b, pneumococcal polysaccharide serotype 9v, pneumococcal polysaccharide serotype 14 - pneumococcal infections; immunization - vaċċini - attiva tilqim kontra mard ikkawżat minn streptococcus pneumoniae serotipi 4, 6b, 9v, 14, 18 c, 19f u 23f (inklużi sepsis, meninġite, pnewmonja, bacteraemia u otiti medja akuta) fit-trabi u tfal minn xahrejn sa ħames snin ta ' età. l-użu ta 'prevenar għandu jkun stabbilit fuq il-bażi ta' rakkomandazzjonijiet uffiċjali filwaqt li jitqiesu l-impatt ta 'mard invażiv fi gruppi differenti ta' età, kif ukoll il-varjabilità tal-epidemjoloġija tas-serotip f'żoni ġeografiċi differenti.